The Vitamin K Cycle
On this page
Direct answer
The vitamin K cycle is a two-enzyme recycling device in the hepatic endoplasmic reticulum that keeps blood-clotting proteins able to bind calcium. Gamma-glutamyl carboxylase uses reduced vitamin K (hydroquinone), carbon dioxide and oxygen to add a second carboxyl group to specific glutamate residues of factors II, VII, IX and X and proteins C, S and Z — converting them to Gla residues — and in doing so oxidises vitamin K to the epoxide. Vitamin K epoxide reductase (VKOR) then regenerates the reduced form. Warfarin inhibits VKOR, so carboxylase stalls, non-functional decarboxylated "PIVKA" proteins accumulate, and the vitamin K-dependent factors fall in the order of their half-lives — factor VII first, within about 6 hours.
What you must remember
- Substrates of carboxylation: prothrombin (II), VII, IX, X, protein C, protein S, protein Z — all synthesised in liver, all needing Gla residues to chelate calcium and assemble on phospholipid membranes; osteocalcin and matrix Gla protein in bone and vessels also cycle through the same chemistry.
- Factor half-life order: VII (about 4-6 hours) falls first, then IX (18-24 h), X (24-48 h), and prothrombin II (48-72 h) — which is why INR rises before antithrombotic protection is complete, mandating heparin bridging for acute thrombosis.
- Protein C paradox: protein C also has a short half-life, so early warfarin transiently depletes inhibition before clotting factors fall — the mechanism of warfarin-induced skin necrosis, classically over fat-rich areas, in protein C-deficient patients given loading doses.
- PIVKA-II (protein induced by vitamin K absence) is the immature prothrombin; it doubles as a laboratory marker of vitamin K deficiency and a hepatocellular carcinoma tumour marker.
- Neonatal prophylaxis: newborns have sterile guts, low placental vitamin K transfer and low breast-milk content (about 1-2 micrograms per litre), so a single intramuscular 1 mg vitamin K at birth is standard Indian practice to prevent haemorrhagic disease of the newborn — classically day 2-5 intracranial or gastrointestinal bleeding.
- Reversal ladder: stopping warfarin, oral vitamin K for mild over-anticoagulation, intravenous vitamin K plus fresh frozen plasma or a four-factor prothrombin complex concentrate for major bleeding; INR reflects the cycle's recovery over 12-24 hours even after parenteral vitamin K.
- Dietary sources: phylloquinone (K1) from green leafy vegetables; menaquinones (K2) from gut flora and fermented foods — a broad-spectrum antibiotic course plus poor intake is the usual ward setup for deficiency.
Warfarin initiation, tracked hour by hour
A patient with a fresh deep vein thrombosis starts warfarin alongside low molecular weight heparin. Day one: VKOR is inhibited, existing factor VII keeps working, nothing measurable happens. By 24 hours factor VII activity has fallen and the INR begins to climb — yet the patient is not protected, because the longer-lived factor X and prothrombin are still circulating; meanwhile protein C, also short-lived, drops, briefly tipping the system toward thrombosis. This is precisely why bridging heparin for at least 5 days and until the INR is therapeutic for 2 consecutive days is protocol, and why a 10 mg loading regimen is avoided in suspected protein C deficiency. When the same patient returns weeks later with an INR of 8 and no bleeding, the cycle explains management: omit a dose, give oral vitamin K cautiously if at high bleeding risk, and know that new factor synthesis is the clock that matters. For major haemorrhage, four-factor PCC replenishes finished factors within minutes while vitamin K restarts the stalled cycle.
Where students slip
The classic muddle is crediting warfarin with "thinning blood" instantly or calling it a heparin potentiator; it has no effect on already-synthesised factors, only on new production through the cycle. Second, students forget that the INR is calibrated for the vitamin K-dependent pathway (it is sensitive to VII, IX, X, II) and says nothing about platelets — a patient bleeding on a therapeutic INR needs a platelet count, not just more vitamin K. Third, gut menaquinones matter in infancy and after prolonged broad-spectrum antibiotics, and Indian exam stems often hide a three-week ceftriaxone course before a vitamin K deficiency bleed.
Frequently asked questions
Which residues does vitamin K-dependent carboxylation modify?
Specific glutamate residues are converted to gamma-carboxyglutamate (Gla), enabling calcium binding and membrane assembly of factors II, VII, IX and X and proteins C and S.
How does warfarin affect the vitamin K cycle?
It inhibits vitamin K epoxide reductase (VKOR), depleting reduced vitamin K so carboxylase cannot function and decarboxylated PIVKA proteins accumulate.
Why is factor VII affected earliest by warfarin?
Its plasma half-life of roughly 4-6 hours is the shortest among the vitamin K-dependent factors, so activity falls first, raising INR before full antithrombotic effect.
Why does the newborn need vitamin K at birth?
Placental transfer is poor, breast milk contains little vitamin K, and the sterile gut makes no menaquinones, so 1 mg intramuscular vitamin K prevents haemorrhagic disease of the newborn.
How is major warfarin-associated bleeding reversed?
Intravenous vitamin K plus four-factor prothrombin complex concentrate (or fresh frozen plasma), because transfused finished factors act immediately while the cycle restarts slowly.